How many institutional investors hold NKTR?

3 tracked institutional investors disclosed a position in NKTR (NEKTAR THERAPEUTICS) in their most recent 13F filing.

Who is the largest institutional holder of NKTR?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in NKTR, valued at $48M.

Where does this NKTR ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

NKTR — NEKTAR THERAPEUTICS

Name: NEKTAR THERAPEUTICS (NKTR) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying NKTR?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence

Institutional Conviction

Strong distribution · 0 buying vs 1 selling last quarter

Macro Tailwind

Macro conditions are mixed for this sector

Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their NKTR position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 57/100 in a Contraction regime).

Supporting evidence

+3 tracked investors reported holding NKTR at their latest filing
+Macro Health is 57/100 in a Contraction regime — historically acceptable for this sectorsource

Contradicting evidence — always shown

−1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
−13F data is disclosed up to 45 days after quarter end — positions may have changed since

Know the limits

· 13F disclosure lag (up to 45 days)
· Tracked investors are a sample, not the whole market
· Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.

About NEKTAR THERAPEUTICS (NKTR)

NEKTAR THERAPEUTICS (NKTR) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $48M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NKTR

/100

Mixed Activity

Added / Increased1

Reduced0

Exited1

BearishBullish

Crowded Trade Score™

How many top investors track NKTR

/100

Emerging Interest

3investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

NKTR Ownership Composition

How NEKTAR THERAPEUTICS is held across tracked investor types, based on reported 13F positions.

Dominant Type

Multi-Strategy / Quant

97% of tracked value

Institutions

tracked investors

Total Reported

$82.6M

combined 13F value

Multi-Strategy / Quant96.9%
Macro3.1%

Multi-Strategy / Quant(2)

96.9%

Macro(1)

3.1%

Tracked investors currently reporting NKTR

1 tracked investor has since exited this position — listed separately below.

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	499K	$34.8M	0.00%	Jun 30, 2026
Izzy Englander	Millennium Management	648.1K	$45.2M	0.02%	Jun 30, 2026
Paul Tudor Jones	Tudor Investment Corp	36.7K	$2.6M	0.00%	Jun 30, 2026

Ken GriffinJun 30, 2026
Citadel Advisors
Shares
499K
Value
$34.8M
% Portfolio
0.00%
Izzy EnglanderJun 30, 2026
Millennium Management
Shares
648.1K
Value
$45.2M
% Portfolio
0.02%
Paul Tudor JonesJun 30, 2026
Tudor Investment Corp
Shares
36.7K
Value
$2.6M
% Portfolio
0.00%

Previously held NKTR

These investors reported NKTR in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

Investor	Firm	Last reported shares	Value then	Last held
Steve Cohen	Point72 Asset Management	13.4K	$961.5K	Mar 31, 2026

Recent activity

Investor	Action	Δ %	Current value	Filing date
Paul Tudor Jones	Unchanged	0.00%	$70.8K	Aug 14, 2024
Paul Tudor Jones	Sold	-100.00%	$0	Nov 14, 2024
Paul Tudor Jones	New	—	$53.3K	May 15, 2024

Paul Tudor Jones
Unchanged
$70.8K(0.00%)Aug 14, 2024
Paul Tudor Jones
Sold
$0(-100.00%)Nov 14, 2024
Paul Tudor Jones
New
$53.3KMay 15, 2024

Frequently asked questions

How many institutional investors hold NKTR?: 3 tracked institutional investors disclosed a position in NKTR (NEKTAR THERAPEUTICS) in their most recent 13F filing.
Who is the largest institutional holder of NKTR?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in NKTR, valued at $48M.
Did institutional ownership of NKTR increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 fully exited NKTR.
Where does this NKTR ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.